Navigation Links
SomaLogic announces agreement with leading global pharma company to accelerate R&D
Date:10/18/2011

Boulder CO, October 18, 2011 SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts.

"We are excited by this opportunity to work with Novartis' world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics," said Larry Gold, CEO of SomaLogic. "We believe that our technology is uniquely able to address the significant drug discovery and development challenges currently faced by biopharmaceutical companies."

Terms of the agreement were not disclosed.

SomaLogic's proprietary proteomic platform is built on two decades of painstaking work to develop an entirely new generation of specific protein-binding reagents that would break open protein biomarker discovery and development in order to drive new diagnostic and therapeutic opportunities. At the heart of SomaLogic's technology are "SOMAmers" (Slow-Offrate Modified Aptamers), an entirely novel class of protein-binding reagents. SOMAmers offer a uniquely powerful combination of specific binding to individual proteins and facile nucleic acid-based quantification, allowing accurate detection and measurement of literally thousands of proteins over a vast range of concentrations in just a few drops of blood or other tissues.


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
617-816-9834
SomaLogic, Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
2. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
3. Trudeau Institute announces its latest discovery in the fight against tuberculosis
4. Biophysical Society announces 2012 Society Fellows
5. White House announces that 2 UCSB faculty members will receive US presidential science awards
6. FASEB announces new client: The Histochemical Society
7. MedNet Solutions Announces the Latest Release of iMedNet EDC
8. FASEB MARC program announces the travel award recipients for the 2011 Leadership Development and Grant Writing Seminar for graduate students, postdoctoral fellows and new assistant professors
9. Trudeau Institute announces new discovery in battle against infections
10. Wiley-Blackwell announces continued growth in impact factor journals
11. The Society for Nutrition Education (SNE) announces Helen Denning Ullrich Award of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... 22, 2010)-- Researchers studying epidemiology of healthcare-associated infections ... found that rates of Clostridium difficile ... Staphylococcus aureus (MRSA). Scientists also discovered that ... diarrhea and more serious intestinal conditions such as ...
... it was found it reduces fat uptake by more than 75 ... Newcastle University are adding seaweed fibre to bread to see if ... eat them. , A team of scientists led by Dr Iain ... one of the world,s largest commercially-used seaweed could reduce the amount ...
... Albert Einstein College of Medicine of Yeshiva University have found ... (TB), a disease responsible for an estimated two million deaths ... issue of Nature Chemical Biology , could lead to ... strains from developing. "This approach is totally different from ...
Cached Biology News:Researchers find Clostridium difficile is more common than MRSA in southeast community hospitals 2Seaweed to tackle rising tide of obesity 2Einstein researchers discover 2 new ways to kill TB 2
(Date:3/30/2015)... , March 30, 2015 ... auf    Richmond Pharmacology ist das erste ... Amyloidose-Zentrum am Royal Free Hospital in ... zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten ... von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen ...
(Date:3/29/2015)... Whitehouse, NJ (PRWEB) March 29, 2015 ... strict deadlines often required by our pharmaceutical manufacturing clients, ... renewed its sponsorship of the Berkenstock Race Team for ... track requires not only speed, but a strong sense ... same principles that lead to success in the quality ...
(Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced the ... the world’s largest business idea competition with $5 million ... million, six $500,000 awards and four $250,000 awards. The ... for prizes that will turn ideas with high growth ... region. , "Last year's successful 43North competition brought ...
Breaking Biology Technology:Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5
... DIEGO, April 27 Volcano Corporation (Nasdaq: VOLC ... products for the diagnosis and treatment of coronary and peripheral ... results for the first quarter of fiscal 2009 on Tuesday, ... its financial results and operating activities open to all interested ...
... Initial Cohort Shows Nine of 14 Evaluable Patients ... Achieved an Objective Tumor Response -- Patient Dosing ... of Enrolling 46 Patients Overall -TUSTIN, Calif., April ... PPHM ), today announced that updated preliminary data ...
... 27 Xspray Microparticles AB, the Swedish,life ... solution for,pharmaceutical particle production based on supercritical ... overcomes many of,the drawbacks of traditional micronization ... well as offering all the advantages of ...
Cached Biology Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial 4Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 2Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 3